

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)



(10) International Publication Number
WO 2022/232178 A1

(51) International Patent Classification:
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/US2022/026395

(22) International Filing Date:
26 April 2022 (26.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/180,247 27 April 2021 (27.04.2021) US

(71) Applicant: **4D MOLECULAR THERAPEUTICS INC.**
[US/US]; 5858 Horton Street, Suite 455, Emeryville, California 94608 (US).

(72) Inventors: **BURNS, Christian**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, California 94608 (US). **CALTON, Melissa**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, California 94608 (US). **LEONG, Meredith**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, California 94608 (US). **SZYMANSKI, Paul**; c/o 4D Molecular Therapeutics Inc., 5858 Horton Street, Suite 455, Emeryville, California 94608 (US).

(74) Agent: **CABRAL, Christopher M.**; Much Shelist PC, 191 N. Wacker Drive, Suite 1800, Chicago, Illinois 60606-1615 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISEASE ASSOCIATED WITH ANGIO-GENESIS

FIG. 1A



(57) Abstract: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration.



WO 2022/232178 A1